Carboxy-Terminal Propeptide of Type 1 Procollagen (P1CP) and Carboxy-Terminal Telopeptide of Type 1 Collagen (1CTP) as Sensitive Markers of Bone Metabolism in Thyroid Disease.

Abstract

Abstract. We measured serum levels of the carboxy-terminal propeptide of type 1 procollagen (P1CP) as a marker of bone formation and the carboxy-terminal telopeptide of type 1 collagen (1CTP) as a marker of bone resorption by RIA in sera from 40 Graves' disease patients and 14 Hashimoto's disease patients before and during treatment. The serum P1CP levels of the untreated Graves' disease were significantly higher than in the controls (176.8 ± 93.5 vs. 107 ± 35 ng/ml, P<0.01), and these levels decreased significantly during treatment with antithyroid drugs. There was a significant statistical correlation between serum P1CP levels and serum total alkaline-phosphatase activity (r=0.61, P<0.01) in the patients with Graves' disease and Hashimoto's disease as a whole. 1CTP levels were also significantly increased in untreated Graves' patients (6.5 ± 2.8 compared with 2.7 ± 1.1 ng/ml in normal subjects, P<0.01). The P1CP/1CTP ratio, which reflects the relative ratio of bone formation to bone resorption, was lower than normal in untreated Graves' disease, but increased following the normalization of thyroid function. The results of this study suggest that the measurement of serum P1CP and 1CTP levels may be useful in evaluating bone metabolism in thyroid disease.

The thyroid and the skeleton

“…Thus thyrotoxicosis is a condition of negative calcium balance and this negative balance may also contribute to the increased fracture risk. In addition, levels of biochemical markers of both bone formation [alkaline phosphatase, osteocalcin, carboxyterminal propeptide of type 1 collagen (P1NP)] and bone resorption [pyridinoline and deoxypyridinoline collagen cross‐links, hydroxyproline, carboxyterminal cross‐linked telopeptide of type 1 collagen (CTX)] are elevated in thyrotoxicosis and generally correlate with thyroid hormone concentrations (Allain & McGregor, 1993; Miyakawa et al ., 1996; Nagasaka et al ., 1997).…”

Relationship Between Serum Levels of Interleukin-6, Tumor Necrosis Factor-.ALPHA. and Bone Turnover Markers in Prostate Cancer Patients.

“…At the time of bone resorption, the carboxyterminal telopeptide of type I collagen (ICTP) is excreted through collagen degradation, and this excretion rate is considered a parameter of the rate of bone degradation [13]. The measurement of serum PICP and ICTP levels has been reported to be useful in evaluating bone metabolism in various diseases [14][15][16][17].…”

Serum Markers of Type I Collagen Synthesis and Degradation in Amyotrophic Lateral Sclerosis

“…In addition, serum levels of PICP are increased in primary biliary cirrhosis [26], alcoholic liver disease [27], systemic sclerosis [28], localized scleroderma [29], essential hypertension [30], primary hyperparathyroidism [31], hypothyroidism [32]and hyperthyroidism [33]. On the other hand, decreased serum PICP levels have been reported in systemic glucocorticoid treatment [34], hypothyroidism [35], multiple myeloma [36], and inflammatory diseases such as rheumatoid arthritis [37]. Since neither ALS patients nor controls in groups A and B in this study had the above conditions or disorders, decreased serum PICP concentrations in ALS patients may be related to the pathogenesis of ALS.…”